ArticleOrthopaedic journal of sports medicine2026
Translation and Validation of the Canadian-French Version of the Banff Patellofemoral Instability Instrument (BPII 2.0-CF).
Article in Orthopaedic journal of sports medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patient-reported outcome measures are essential tools for assessing function and quality of life. The Banff Patellofemoral Instability Instrument Version 2.0 (BPII 2.0) is specifically designed to evaluate adolescents and adults experiencing patellofemoral instability (PFI). Purpose: Because no French version was available, this study aimed to translate and validate a Canadian-French (CF) version of the BPII 2.0. Study Design: Cohort study (Diagnosis); Level of evidence, 3. Methods: The BPII 2.0 was translated using a forward-backward translation method (BPII 2.0-CF), following guidelines from the American Association of Orthopaedic Surgeons and the Institute for Work & Health. Participants aged ≥14, fluent in French, and with a confirmed diagnosis of PFI were included. Patients completed the questionnaire at their initial consultation, 7 days later, and 6 months after treatment. Construct validity was assessed through Spearman correlation with the Kujala score. Internal consistency was evaluated using the Cronbach alpha coefficient, and test-retest reliability using the intraclass correlation coefficient (ICC). Responsiveness to change was analyzed using the Wilcoxon signed-rank test and the corresponding effect size Results: A total of 45 participants were included (female, n = 33; 73%), with a median age of 21 years (range, 14-54). The median symptom duration before consultation was 48 months (range, 0.5-480.0). Mean ± SD BPII 2.0-CF scores were 38.46 ± 14.48 (N = 45), 39.52 ± 15.99 (n = 34), and 60.99 ± 20.24 (n = 29) at baseline, day 7, and 6 months after surgery, respectively. No floor or ceiling effects were observed. The construct validity of the translated BPII 2.0 and the French Kujala score at baseline was fair and statistically significant ( Conclusion: The CF version of the BPII 2.0 is a valid, reliable, and appropriate tool for assessing patients with PFI. The rigorous translation and validation process supports its use in Francophone clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.